Toda et al. observed that KRAS mutation altered the amino acid metabolism in CRC cells by reducing aspartate level and increasing asparagine level to maintain cell viability and tumor growth under the glutamine-depleted condition (Toda et al., 2016). The gene discussed is KRAS; the disease is colorectal carcinoma.